EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients

@article{Li2011EGFRFI,
  title={EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients},
  author={Yu-hong Li and Fang Wang and Lin Shen and Yan-ming Deng and Qiong Shao and Fen Feng and Xin An and Fenghua Wang and Zhi-Qiang Wang and Rui-hua Xu and Jian-Yong Shao},
  journal={Clinical Cancer Research},
  year={2011},
  volume={17},
  pages={382 - 390}
}
Purpose: Metastatic colorectal cancer patients with low epidermal growth factor receptor (EGFR) gene copy number are unlikely to respond to anti-EGFR monoclonal antibody (mAb) treatment. The objective of this study was to investigate EGFR fluorescence in situ hybridization (FISH) patterns of chromosome 7 disomy with efficacy of cetuximab therapy in metastatic colorectal cancer patients. Experimental Design: We detected the EGFR FISH patterns and KRAS status in 74 tumors from cetuximab-treated… 

Figures and Tables from this paper

EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis
TLDR
Among the anti-EGFR-treated patients, increased EGFR GCN appears to be associated with improved survival outcomes, and the effect on survival seems to be related to patients receiving the line of treatment.
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
TLDR
Her2 gene copy number status may influence the clinical response to anti-EGFR-targeted therapy in mCRC patients, and is significantly correlated with different clinical behaviours.
High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
TLDR
A high EGFR copy number may predict benefit from TKIs treatment for NSCLC patients with wild-type EGFR, and FISH + had no association with improved PFS in EGFR-mutated patients, suggesting a combined analysis of EGFR FISH and mutation is an effective predictor of EG FR-TKI therapy.
EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.
OBJECTIVE The epidermal growth factor receptor (EGFR) inhibitors monoclonal antibodies (MoAbs) have already shown the therapeutic effectiveness in patients with metastatic colorectal cancer (mCRC).
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
TLDR
How to further improve the predictive value of anti-EGFR therapies and how to also try and avoid futile treatment for wild-type KRAS colorectal cancer patients are focused on.
Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
TLDR
The coexistence of genetic alterations in cancer genes may explain primary resistance to EGFR-TKIs in advanced NSCLC patients with activated EGFR mutations.
Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer
TLDR
There were significant correlations between EGFR expression and the number of polysomic cells and the presence of high polysomy of chromosome 7, but EG FR expression was not correlated with p-Akt or p-mTOR expression, nor with the other clinicopathic factors recorded in this study.
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study
TLDR
Molecular diagnosis of EGFR gene copy number by FISH varied largely among pathology centres, with fluctuations covering the whole range of proposed cut-offs of predictive usefulness from literature.
Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients
TLDR
MET GCN gain and CEP7 polysomy could predict a poor outcome in CRC patients, especially CEP8 polysome has the most powerful prognostic impact in stage II/III CRC patients.
...
1
2
3
...

References

SHOWING 1-10 OF 22 REFERENCES
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
TLDR
In a larger and more homogeneous series than in previous studies, exploratory data suggest that mCRC patients with tumors distinguishable by FISH analysis of EGFR as homogenously disomic or with low chromosome 7 polysomy have a reduced likelihood of response to panitumumab.
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
TLDR
CRC patients with high EGFR gene copy number have an increased likelihood to respond to cetuximab therapy, and Prospective clinical trials with a careful standardization of assay conditions and pattern interpretation are urgently needed.
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study
TLDR
The association between increased EGFR GCN and outcome after cetuximab is confirmed, but because of reproducibility concerns, any decision making based on published cutoff points is not warranted.
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
TLDR
An increase in EGFR copy number may be associated with cetuximab response but is a rare event in CRC, KRAS mutations are associated with low response rate but do not preclude any cetukimab-based combination efficacy and EGFR exon 13 variant (R521K) may predict for cetUXimab benefit.
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
TLDR
KRAS mutations are a predictor of resistance to cetuximab therapy and are associated with a worse prognosis, and the EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment.
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
TLDR
The scoring system used in the studies conducted at the University of Colorado Cancer Center in which a significant association was found between increased EGFR copy numbers and clinical outcome to TKIs is detailed, and interpretative guidelines for molecular stratification of NSCLC patients for TKI therapy are proposed.
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
  • C. Chung, K. Ely, F. Hirsch
  • Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
High EGFR gene copy number by FISH is frequent in HNSCC and is a poor prognostic indicator, and additional investigation is indicated to determine the biologic significance and implications for EGFR inhibitor therapies in H NSCC.
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
TLDR
These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetUXimab.
...
1
2
3
...